These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36239466)

  • 1. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity.
    Smith CW; Harbi MH; Garcia-Quintanilla L; Rookes K; Brown H; Poulter NS; Watson SP; Nicolson PLR; Thomas MR
    J Thromb Haemost; 2022 Dec; 20(12):2939-2952. PubMed ID: 36239466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
    Busygina K; Jamasbi J; Seiler T; Deckmyn H; Weber C; Brandl R; Lorenz R; Siess W
    Blood; 2018 Jun; 131(24):2605-2616. PubMed ID: 29559479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.
    Karel MFA; Tullemans BME; D'Italia G; Lemmens TP; Claushuis TAM; Kuijpers MJE; Cosemans JMEM
    Thromb Res; 2022 Apr; 212():72-80. PubMed ID: 35247800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-GPVI nanobody blocks collagen- and atherosclerotic plaque-induced GPVI clustering, signaling, and thrombus formation.
    Jooss NJ; Smith CW; Slater A; Montague SJ; Di Y; O'Shea C; Thomas MR; Henskens YMC; Heemskerk JWM; Watson SP; Poulter NS
    J Thromb Haemost; 2022 Nov; 20(11):2617-2631. PubMed ID: 35894121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NADPH oxidase 1/4 dual inhibitor setanaxib suppresses platelet activation and thrombus formation.
    Oh EB; Shin HJ; Yu H; Jang J; Park JW; Chang TS
    Life Sci; 2024 Nov; 357():123061. PubMed ID: 39293714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI.
    Penz S; Reininger AJ; Brandl R; Goyal P; Rabie T; Bernlochner I; Rother E; Goetz C; Engelmann B; Smethurst PA; Ouwehand WH; Farndale R; Nieswandt B; Siess W
    FASEB J; 2005 Jun; 19(8):898-909. PubMed ID: 15923400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
    Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
    Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.
    Tullemans BME; Karel MFA; Léopold V; Ten Brink MS; Baaten CCFMJ; Maas SL; de Vos AF; Eble JA; Nijziel MR; van der Vorst EPC; Cosemans JMEM; Heemskerk JWM; Claushuis TAM; Kuijpers MJE
    EJHaem; 2021 Nov; 2(4):685-699. PubMed ID: 35845214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
    French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
    J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies.
    Jamasbi J; Megens RT; Bianchini M; Münch G; Ungerer M; Faussner A; Sherman S; Walker A; Goyal P; Jung S; Brandl R; Weber C; Lorenz R; Farndale R; Elia N; Siess W
    J Am Coll Cardiol; 2015 Jun; 65(22):2404-15. PubMed ID: 26046734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
    Alenazy FO; Harbi MH; Kavanagh DP; Price J; Brady P; Hargreaves O; Harrison P; Slater A; Tiwari A; Nicolson PLR; Connolly DL; Kirchhof P; Kalia N; Jandrot-Perrus M; Mangin PH; Watson SP; Thomas MR
    J Thromb Haemost; 2023 Nov; 21(11):3236-3251. PubMed ID: 37541591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.
    Smith CW; Campos J; Brown HC; Jooss NJ; Ivanova VS; Harbi M; Garcia-Quintanilla L; Jossi S; Perez-Toledo M; Rookes K; Brill A; Theodore LN; Owens T; LaStant J; Foulke MC; Mukai S; Francesco M; Storek M; Hicks A; Langrish C; Nunn PA; Cunningham AF; Chauhan A; Thomas MR; Watson SP; Nicolson PLR
    Blood Adv; 2024 Nov; 8(21):5557-5570. PubMed ID: 38968150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
    Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
    Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.
    Bye AP; Unsworth AJ; Desborough MJ; Hildyard CAT; Appleby N; Bruce D; Kriek N; Nock SH; Sage T; Hughes CE; Gibbins JM
    Blood Adv; 2017 Dec; 1(26):2610-2623. PubMed ID: 29296914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
    Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.